The term human T cell leukemia/lymphoma virus (HTLV) denotes a unique family of T cell tropic human type C retroviruses (1, 2). 1 We studied the generation of cytotoxic T lymphocytes (CTL) derived from a patient who had an unusually long survival after therapy for an HTLV-associated T cell iymphoma. The purpose of this paper is to report the characteristics of a T cell growth factor-dependent line of CTL from this patient which lyses autologous tumor cells infected with HTLV. The data suggest a form of cytotoxic activity restricted by products of the major histocompatibility complex (MHC).
clear cells (PBM) were prepared from heparinized blood of patient MJ and normal individuals by Ficoll-Isopaque gradient centrifugation. Aliquots of PBM (107 cells) from patient MJ or a normal individual were co-cultured with 108 irradiated (12,000 rad) MJ tumor cells in upright flasks (3050; Costar, Cambridge, MA) at 37 °C in 5% CO2-containing humidified air in I0 ml of RPMI 1640 supplemented with 10% heat-inactivated human AB serum, 4 mM L-glutamine, 5 X 10 -5 M 2-mercaptoethanol, 50 U/ml penicillin, and 50 ~g/ml streptomycin. After day 6, these cultured cells were continuously exposed to 20% lectin-depleted T cell growth factor (ld-TCGF) containing RPMI 1640 with 10% heat-inactivated fetal calf serum (FCS) without further use of human serum. The cultures were repeatedly stimulated with irradiated MJ tumor cells at 7-14-d intervals.
Cytotoxicity Assay. A 4-h 5~Cr-release assay was carried out in round-bottomed microtiter plates (Linbro Chemical Co., Hamden, CT). 10,000 5~Cr-labeled target cells were mixed with various numbers of effector cells in 150 #1 RPMI 1640 supplemented with 4% FCS. After the plates were incubated for 4 h at 37°C in 5% COs-containing humidified air, supernatants were harvested with the Titertek Supernatant Collection System and measured for radioactivity. The percentage specific 5~Cr release was determined by the following formula: 100 x [(release in test -spontaneous release)/(maximum releasespontaneous release)]. Spontaneous release was always <20% of maximum release for all target cells.
Competitive Cold-Target Inhibition Assays. The effectors were dispersed in 100 ~1 RPMI 1640 supplemented with 4% FCS and various numbers of unlabeled target cells were added in 50 ~1 medium. Then ~'Cr-labeled MJ tumor cells (104 cells/well) were added in 50 #1 of medium. The ratios of effector/labeled target cells were 5:1 or 10:1. The plates were then incubated and processed using the usual cytotoxic assay to determine specific 5~Cr release. 
Results
Generation of a Specific CTL Line from the Patient. Fresh PBM from patient MJ did not mediate specific cytotoxicity (data not shown). However, on day 20 of culture the patient's cells mediated a substantial level of specific cytotoxicity against MJ tumor cells (Fig. 1A-l) . By contrast, a normal individual's PBM exposed to MJ tumor cells and cultured under the same conditions did not mediate specific cytotoxicity and killed a variety of target cells (Fig. 1 B) .
After repeated cycles of stimulation with MJ tumor cells and expansion with /d-TCGF, the cytotoxicity of the cultured cells from the patient against various tumor targets other than his autologous tumor cells was progressively reduced. On day 27 and beyond, the patient's cultured cells were cytotoxic specifically for his own tumor cells in effector/target ratios of 5:1 or less compared with a variety of unrelated HTLV-infected and uninfected target cells ( Fig. 1 A-2 and A-3). The specificity was confirmed by competitive cold-target inhibition studies, which showed a linear inhibition of cytotoxic effector activity by the addition of unlabeled MJ tumor cells (Fig. 2) . The CTL line has now been maintained for >150 d.
Almost all cells in the CTL line after 22 d in culture reacted with OKT3 (96-100%) and OKT8 (98-100%) antibodies; 43 and 92% reacted with anti-Tac and HLA-DR antibodies, respectively. There were <3% OKT4 reactive cells. How- ever, in the MJ tumor cell population, we observed a different phenotypic profile: 0-17% of the cells were reactive with OKT3, 61-68% were reactive with OKT4, and <1% were reactive with OKT8.
HLA Restriction of Cytotoxic Activity. The specific T cell-mediated lysis of virally infected target cells requires an associative recognition of MHC-encoded antigens in a variety of settings (4) . Consequently, we tested the CTL from patient MJ (MJ CTL), MJ tumor, and various cell lines for expression of HLA alloantigens (Table I ) using the microcytoxicity technique (5). MJ CTL failed to kill various HTLV-infected target cells that did not share HLA antigens expressed by MJ CTL. However, they were cytotoxic against MJ tumor cells and WA tumor cells, which did share A1, B8, Cw7, and DR3 ( Fig.   1 A-3) , suggesting an HLA-restricted form ofcytotoxicity. To confirm and extend these observations, cold-target competition assays were performed ( Fig. 2B and  C) . The cytotoxic activity of MJ CTL against MJ tumor cells was selectively blocked by unlabeled MJ and WA tumor cells but not by any other HLAunmatched cells tested.
To further characterize the specificity of MJ'CTL, we tested EBV-transformed cells from normal individuals who shared A 1, B8, and DR antigens with patient MJ. Moreover, we tested an EBV-transformed line derived from the index patient himself. MJ CTL did not kill these various HLA-matched control target cells (Table II) . The cytotoxicity of MJ CTL against autologous MJ tumor cells was not inhibited by the partially HLA-matched MM-B and GT-B cells as cold targets (Fig. 2 C) . These data suggest that the cytotoxicity of MJ CTL is directed against HTLV-related antigen(s) and that HTLV-specific cytolytic activity is restricted by products linked to the MHC. 997 Discussion This initial characterization of a cytotoxic T cell response to a human retrovirus-associated tumor establishes a parallel with the well-studied animal models of immune responses to retrovirus-induced tumors (6) . This is of interest from several perspectives. The first involves the relationship between cell-mediated immunity to type C retroviruses and leukemogenesis. There are data suggesting that chronic immunostimulation and the profound general amplification of the immune system resulting from persistent viremia eventually leads to somatic errors, bringing about a neoplastic transformation of proliferating T cells (7) .
In a related point of view, T cells "transformed" by retroviruses might represent precisely those lymphocytes whose antigen specificity is directed against viral determinants (receptor-mediated leukemogenesis theory) (8) , and continuous exposure to the stimulating antigen would be necessary in maintaining the T cell-transformed state. The receptor-mediated leukemogenesis theory per se requires no event beyond the development of the matching receptor and ligand in an appropriate microenvironment. Accordingly, in certain settings, susceptibility to viral leukemogenesis could paradoxically correlate with various cellmediated immune responses (including the generation of cytotoxic T cells). If this hypothesis is correct, the induction of immune tolerance to virus-associated antigen(s) would decrease the likelihood of vitally induced transformation. An additional perspective from which the current results may be viewed relates to the role of the host ceil-mediated immune response in the control of tumor growth. Several studies have shown that the emergence of specific cell-mediated immunity in the context of a regressing tumor confers resistance to subsequent challenge with the same tumor (9) . Such immunity results from the generation of regulatory and cytotoxic effector T cell responder populations, and this immunity can be adoptively transferred to unimmunized syngeneic hosts.
Of perhaps greater clinical relevance are reports involving murine models of adoptive immunotherapy or chemoimmunotherapy in which fresh or cultured immune T cells specific for retrovirus-induced tumors were able to effect complete tumor regression upon transfer to syngeneic hosts already bearing otherwise lethal, disseminated tumors (10, 11) . The potential clinical applications of cytotoxic T cells propagated in vitro are topics for future research.
Summary
Lymphocytes from a patient who had an unusually long survival after therapy for a human T cell leukemia/lymphoma virus (HTLV)-associated T cell lymphoma were stimulated in vitro with an autoiogous tumor cell line, and the generation of cytotoxic T lymphocytes (CTL) was studied. CTL generated were directed against autologous HTLV-associated tumor cells. These propagated CTL were OKT3+, OKT4-, and OKT8+. The cytotoxic activity required target tumor cells that were infected with HTLV and also expressed histocompatibility antigens in common with the patient, suggesting a major histocompatibility complex-restricted associative recognition of target antigens expressed on the tumor cell membrane. 21 June 1983. 
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